Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (LLY)
NYSE:LLY
Holding LLY?
Track your performance easily
LLY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$614.82 - $972.53
Previous CloseN/A
Volume1.27M
Average Volume (3M)3.62M
Market Cap
$719.20B
Enterprise Value$829.46B
Total Cash (Recent Filing)$6.04B
Total Debt (Recent Filing)$8.37B
Price to Earnings (P/E)82.9
Beta0.62
Next Earnings
Feb 06, 2025EPS Estimate
5.3Next Dividend Ex-Date
Feb 14, 2025Dividend Yield0.69%
Share Statistics
EPS (TTM)9.14
Shares Outstanding949,315,700
10 Day Avg. Volume4,514,134
30 Day Avg. Volume3,619,286
Standard Deviation0.09
R-Squared0.06
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)17.60
Price to Cash Flow (P/CF)48.40
P/FCF Ratio76.20
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue20.30
Enterprise Value/Gross Profit30.67
Enterprise Value/Ebitda67.32
Forecast
1Y Price Target
$1,024.00Price Target Upside41.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
Eli Lilly & Co News
Bulls Say, Bears Say
Bulls Say
Financial Performance And GuidanceThe 2025 guide provides a counter to the 2024 cut, with more robust growth than Street estimates, driven by improved outlook for additional Lilly launches.
Product Approval And Market ExpansionTirzepatide's US approval for obstructive sleep apnea and its superior results compared to semaglutide are expected to drive significant US growth.
Strategic AcquisitionThe acquisition of Scorpion's PI3Ka is seen as a step in the right direction for LLY Oncology and is considered NPV-positive.
Bears Say
Earnings ReliabilityThe company missed expectations for two quarters in a row, raising questions about the reliability of its guidance.
Guidance CutLilly's management announced a guidance cut for 2024, reducing expected revenue by $700M at the midpoint to ~$45B, driven by lower than expected growth for Mounjaro and Zepbound and lower channel inventory stocking.
Revenue ShortfallQ4 revenues came in lower than estimates, driven by misses in key products Mounjaro and Zepbound.
---
Ownership Overview
10.35% Insiders
22.59% Mutual Funds
0.53% Other Institutional Investors
50.44% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LLY FAQ
What was Eli Lilly & Co’s price range in the past 12 months?
Eli Lilly & Co lowest stock price was $614.82 and its highest was $972.53 in the past 12 months.
What is Eli Lilly & Co’s market cap?
Eli Lilly & Co’s market cap is $719.20B.
When is Eli Lilly & Co’s upcoming earnings report date?
Eli Lilly & Co’s upcoming earnings report date is Feb 06, 2025 which is in 15 days.
How were Eli Lilly & Co’s earnings last quarter?
Eli Lilly & Co released its earnings results on Oct 30, 2024. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.421 by -$0.241.
Is Eli Lilly & Co overvalued?
According to Wall Street analysts Eli Lilly & Co’s price is currently Undervalued.
Does Eli Lilly & Co pay dividends?
Eli Lilly & Co pays a Quarterly dividend of $5.196 which represents an annual dividend yield of 0.69%. See more information on Eli Lilly & Co dividends here
What is Eli Lilly & Co’s EPS estimate?
Eli Lilly & Co’s EPS estimate is 5.3.
How many shares outstanding does Eli Lilly & Co have?
Eli Lilly & Co has 949,315,700 shares outstanding.
What happened to Eli Lilly & Co’s price movement after its last earnings report?
Eli Lilly & Co reported an EPS of $1.18 in its last earnings report, missing expectations of $1.421. Following the earnings report the stock price went down -6.281%.
Which hedge fund is a major shareholder of Eli Lilly & Co?
Among the largest hedge funds holding Eli Lilly & Co’s share is PRIMECAP Management Co. It holds Eli Lilly & Co’s shares valued at 16B.
---
Eli Lilly & Co Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,024.00 (41.10% Upside)
$1,024.00 (41.10% Upside)
Blogger Sentiment
Bullish
LLY Sentiment 83%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.14%
12-Months-Change
Fundamentals
Return on Equity
58.78%
Trailing 12-Months
Asset Growth
30.55%
Trailing 12-Months
Company Description
Eli Lilly & Co
Eli Lilly & Co (LLY) is a global pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of innovative medicines. Headquartered in Indianapolis, Indiana, the company primarily operates in the pharmaceutical sector, focusing on human pharmaceutical products. Eli Lilly is renowned for its contributions in areas such as endocrinology, oncology, immunology, neuroscience, and cardiovascular health. The company’s product portfolio includes well-known medications such as Trulicity, Humalog, and Alimta, among others.
---
LLY Company Deck
---
LLY Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and product performance, driven by new product launches and pipeline advancements. However, there were some challenges such as the decline in Trulicity revenue and inventory management issues impacting sales. Despite these, the company's financial health and future prospects remain robust.Read More>---
LLY Revenue Breakdown
63.86% U.S.
18.09% Europe
8.63% Other foreign countries
4.90% Japan
4.51% China
---
LLY Stock 12 Month Forecast
Average Price Target
$1,024.00
▲(41.10% Upside)
Technical Analysis
Best Analysts Covering LLY
1 Year
1 Year Success Rate
34/37 ratings generated profit
1 Year Average Return
+37.24%
reiterated a buy rating 8 days ago
Copying Geoff Meacham's trades and holding each position for 1 Year would result in 91.89% of your transactions generating a profit, with an average return of +37.24% per trade.
---